Theravance Biopharma, Inc. (TBPH) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $16.76 (+0.12%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 4, 2026 | Mayank Mamtani | B.Riley Financial | $14.00 | -16.5% |
| Nov 13, 2024 | David Risinger | Leerink Partners | $10.00 | -40.3% |
| Aug 6, 2024 | Douglas Tsao | H.C. Wainwright | $15.00 | -10.5% |
| Apr 12, 2024 | Julian Harrison | BTIG | $21.00 | +25.3% |
Top Analysts Covering TBPH
TBPH vs Sector & Market
| Metric | TBPH | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.30 | 2.24 | 2.41 |
| Analyst Count | 10 | 8 | 18 |
| Target Upside | +61.1% | +1150.2% | +14.9% |
| P/E Ratio | 8.26 | 6.86 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $20M | $22M | $22M | 4 |
| 2026-09-30 | $20M | $22M | $26M | 2 |
| 2026-12-31 | $50M | $56M | $66M | 3 |
| 2027-03-31 | $53M | $58M | $69M | 3 |
| 2027-06-30 | $55M | $61M | $73M | 2 |
| 2027-09-30 | $58M | $64M | $76M | 2 |
| 2027-12-31 | $61M | $67M | $80M | 3 |
| 2028-12-31 | $78M | $93M | $112M | 5 |
| 2029-12-31 | $82M | $97M | $117M | 2 |
| 2030-12-31 | $86M | $103M | $123M | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $0.05 | $0.11 | $0.17 | 1 |
| 2026-09-30 | $0.19 | $0.21 | $0.26 | 1 |
| 2026-12-31 | $1.46 | $1.67 | $2.08 | 1 |
| 2027-03-31 | $0.37 | $0.42 | $0.53 | 1 |
| 2027-06-30 | $0.58 | $0.66 | $0.83 | 1 |
| 2027-09-30 | $0.36 | $0.41 | $0.50 | 1 |
| 2027-12-31 | $0.97 | $1.11 | $1.38 | 1 |
| 2028-12-31 | $0.09 | $0.84 | $1.51 | 5 |
| 2029-12-31 | $0.75 | $0.95 | $1.19 | 1 |
| 2030-12-31 | $0.90 | $1.15 | $1.44 | 1 |
Frequently Asked Questions
What is the analyst consensus for TBPH?
The consensus among 10 analysts covering Theravance Biopharma, Inc. (TBPH) is Buy with an average price target of $27.00.
What is the highest price target for TBPH?
The highest price target for TBPH is $21.00, set by Julian Harrison at BTIG on 2024-04-12.
What is the lowest price target for TBPH?
The lowest price target for TBPH is $10.00, set by David Risinger at Leerink Partners on 2024-11-13.
How many analysts cover TBPH?
10 analysts have issued ratings for Theravance Biopharma, Inc. in the past 12 months.
Is TBPH a buy or sell right now?
Based on 10 analyst ratings, TBPH has a consensus rating of Buy (2.30/5) with a +61.1% upside to the consensus target of $27.00.
What are the earnings estimates for TBPH?
Analysts estimate TBPH will report EPS of $0.11 for the period ending 2026-06-30, with revenue estimated at $22M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.